pre-update Archives

Video

From Development to Patient Impact: Biohaven’s Nurtec™ Success Story

To learn more about Biohaven's success story, read our case study. Read the case study

CertaraSeptember 13, 2024

Blog

4 Ways That Mechanistic Modeling Accelerates Bispecific (and Multispecific) Antibody Drug Development

With nine FDA-approved drugs today, 100+ in clinical development and several hundred in the preclinical…

CertaraSeptember 12, 2024

Fact Sheet

From Protocol to Submission: Essential Regulatory Writing Resources

CertaraSeptember 11, 2024

Press Coverage

Fierce Pharma – IRA biosimilar measure intended to boost uptake so far has ‘limited’ impact: report

Check out this article in Fierce Pharma to learn how Certara's US Market Access team…

CertaraSeptember 11, 2024

Poster

Dose Selection for DuoBody®-PD-L1x4-1BB (GEN1046)

Abstract DuoBody®-PD-L1x4-1BB (GEN1046) is an investigational, first-in-class, bispecific antibody designed to elicit an antitumor immune…

CertaraSeptember 9, 2024

Poster

Optimizing Avidity of Bispecific Drugs

Abstract Bispecific drugs have great potential to improve tissue selectivity through avid binding interactions but…

CertaraSeptember 9, 2024

Conference

2024 CDISC Korea Interchange

CertaraSeptember 9, 2024

Poster

Effects of Tissue Targeting Bispecifics on Therapeutic Window

Abstract Objectives: The presence of target receptors in non-target tissues can reduce the therapeutic window…

CertaraSeptember 9, 2024

Announcement

CERTARA BRINGS ASIA-PACIFIC DRUG DEVELOPMENT LEADERS TOGETHER AT CERTAINTY Conference.

Certara client forums in China, Korea, and Japan support collaboration and networking among drug developers…

CertaraSeptember 3, 2024

Publication

Application of physiologically based pharmacokinetic modeling of novel drugs approved by the U.S. food and drug administration

The article from the European Journal of Pharmaceutical Sciences reviews the role of Physiologically Based…

CertaraSeptember 1, 2024

pre-update

From Development to Patient Impact: Biohaven’s Nurtec™ Success Story

4 Ways That Mechanistic Modeling Accelerates Bispecific (and Multispecific) Antibody Drug Development

From Protocol to Submission: Essential Regulatory Writing Resources

Fierce Pharma – IRA biosimilar measure intended to boost uptake so far has ‘limited’ impact: report

Dose Selection for DuoBody®-PD-L1x4-1BB (GEN1046)

Optimizing Avidity of Bispecific Drugs

2024 CDISC Korea Interchange

Effects of Tissue Targeting Bispecifics on Therapeutic Window

CERTARA BRINGS ASIA-PACIFIC DRUG DEVELOPMENT LEADERS TOGETHER AT CERTAINTY Conference.

Application of physiologically based pharmacokinetic modeling of novel drugs approved by the U.S. food and drug administration

Newsletter sign up

Quick links

Solutions

Contact